drugset / Trial / NCT06769113
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.
Timeline
- Start
- 2025-01-26
- Primary completion
- 2026-10-31
- Completion
- 2027-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 2.5 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 3 mg/kg | Intravenous |